GB-266

N/A

Report date: 2022/08/26 13:50:25

Base Information

Drug NameGB-266
Drug Alias NameGB-266
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Lymphocyte activation gene 3 protein inhibitors
TargetsProgrammed death-ligand 1Lymphocyte activation gene 3 protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A